Ovid Therapeutics Inc.

Ovid is a biopharmaceutical company that develops small molecule medicines to treat central nervous system disorders. The company focuses on addressing conditions characterized by neuronal hyperexcitability, including rare epilepsies and psychiatric disorders. Its primary clinical-stage programs include OV329, a GABA-aminotransferase inhibitor evaluated for focal onset seizures, tuberous sclerosis complex, and infantile spasms, alongside a library of potassium-chloride cotransporter 2 direct activators, led by the oral candidate OV4071. Its targeted patient populations comprise individuals suffering from drug-resistant seizures, schizophrenia, and psychoses associated with Parkinson's disease and Lewy body dementia.

The company operates with a team of 23 professionals, including three medical doctors and eight scientists holding doctorate degrees. Its research and development assets include a collection of more than 100 direct activator molecules and multiple clinical development initiatives. The provided text indicates regulatory and clinical trial activities in Australia and the United States, but it does not disclose the location of the company's headquarters.

Summary of the business section of Ovid Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of December 31, 2025, we had 23 full-time employees, the majority of whom were primarily engaged in research and development activities, including three individuals with MD degrees and eight professionals with PhD degrees specializing in the sciences.”